Literature DB >> 32415541

Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes.

Christoph Mueller1,2, Christeena John3, Gayan Perera3, Dag Aarsland3,4, Clive Ballard3,5, Robert Stewart3,6.   

Abstract

Antipsychotic treatments are associated with safety concerns in people with dementia. The authors aimed to investigate whether risk of adverse outcomes related to antipsychotic prescribing differed according to major neuropsychiatric syndromes-specifically psychosis, agitation, or a combination. A cohort of 10,106 patients with a diagnosis of dementia was assembled from a large dementia care database in South East London. Neuropsychiatric symptoms closest to first dementia diagnosis were determined according to the Health of the Nation Outcome Scales' mental and behavioural problem scores and the sample was divided into four groups: 'agitation and psychosis', 'agitation, but no psychosis', 'psychosis, but no agitation', and 'neither psychosis nor agitation'. Antipsychotic prescription in a one-year window around first dementia diagnosis was ascertained as exposure variable through natural language processing from free text. Cox regression models were used to analyse associations of antipsychotic prescription with all-cause and stroke-specific mortality, emergency hospitalisation and hospitalised stroke adjusting for sixteen potential confounders including demographics, cognition, functioning, as well as physical and mental health. Only in the group 'psychosis, but no agitation' (n = 579), 30% of whom were prescribed an antipsychotic, a significant antipsychotic-associated increased risk of hospitalised stroke was present after adjustment (adjusted hazard ratio (HR) 2.16; 95% confidence interval (CI) 1.09-4.25). An increased antipsychotic-related all-cause (adjusted HR 1.14; 95% CI 1.04-1.24) and stroke-specific mortality risk (adjusted HR 1.28; 95% CI 1.01-1.63) was detected in the whole sample, but no interaction between the strata and antipsychotic-related mortality. In conclusion, the adverse effects of antipsychotics in dementia are complex. Stroke risk may be highest when used in patients presenting with psychosis without agitation, indicating the need for novel interventions for this group.

Entities:  

Keywords:  Antipsychotics; Dementia; Mortality; Prognosis; Risk stratification; Stroke

Year:  2020        PMID: 32415541     DOI: 10.1007/s10654-020-00643-2

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  40 in total

Review 1.  Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis.

Authors:  Alicia Ruelaz Maher; Margaret Maglione; Steven Bagley; Marika Suttorp; Jian-Hui Hu; Brett Ewing; Zhen Wang; Martha Timmer; David Sultzer; Paul G Shekelle
Journal:  JAMA       Date:  2011-09-28       Impact factor: 56.272

2.  Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

Authors:  Lon S Schneider; Pierre N Tariot; Karen S Dagerman; Sonia M Davis; John K Hsiao; M Saleem Ismail; Barry D Lebowitz; Constantine G Lyketsos; J Michael Ryan; T Scott Stroup; David L Sultzer; Daniel Weintraub; Jeffrey A Lieberman
Journal:  N Engl J Med       Date:  2006-10-12       Impact factor: 91.245

3.  Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the Cache County Dementia Progression Study.

Authors:  Matthew E Peters; Sarah Schwartz; Dingfen Han; Peter V Rabins; Martin Steinberg; Joann T Tschanz; Constantine G Lyketsos
Journal:  Am J Psychiatry       Date:  2015-01-13       Impact factor: 18.112

4.  Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study.

Authors:  Toru Okura; Brenda L Plassman; David C Steffens; David J Llewellyn; Guy G Potter; Kenneth M Langa
Journal:  J Am Geriatr Soc       Date:  2011-03       Impact factor: 5.562

Review 5.  The link between psychosis and aggression in persons with dementia: a systematic review.

Authors:  Denis Shub; Valdesha Ball; Asghar-Ali Ali Abbas; Aruna Gottumukkala; Mark E Kunik
Journal:  Psychiatr Q       Date:  2010-06

6.  Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study.

Authors:  Katherine A Treiber; Constantine G Lyketsos; Chris Corcoran; Martin Steinberg; Maria Norton; Robert C Green; Peter Rabins; David M Stein; Kathleen A Welsh-Bohmer; John C S Breitner; JoAnn T Tschanz
Journal:  Int Psychogeriatr       Date:  2008-02-21       Impact factor: 3.878

7.  Clustering of behavioural and psychological symptoms in dementia (BPSD): a European Alzheimer's disease consortium (EADC) study.

Authors:  M Petrovic; C Hurt; D Collins; A Burns; V Camus; R Liperoti; A Marriott; F Nobili; P Robert; M Tsolaki; B Vellas; F Verhey; E J Byrne
Journal:  Acta Clin Belg       Date:  2007 Nov-Dec       Impact factor: 1.264

Review 8.  Psychosis in Alzheimer's disease.

Authors:  Patrick S Murray; Sanjeev Kumar; Mary Ann A Demichele-Sweet; Robert A Sweet
Journal:  Biol Psychiatry       Date:  2013-10-06       Impact factor: 13.382

Review 9.  The prevalence of neuropsychiatric symptoms in Alzheimer's disease: Systematic review and meta-analysis.

Authors:  Qing-Fei Zhao; Lan Tan; Hui-Fu Wang; Teng Jiang; Meng-Shan Tan; Lin Tan; Wei Xu; Jie-Qiong Li; Jun Wang; Te-Jen Lai; Jin-Tai Yu
Journal:  J Affect Disord       Date:  2015-10-24       Impact factor: 4.839

Review 10.  Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.

Authors:  I G McKeith; D W Dickson; J Lowe; M Emre; J T O'Brien; H Feldman; J Cummings; J E Duda; C Lippa; E K Perry; D Aarsland; H Arai; C G Ballard; B Boeve; D J Burn; D Costa; T Del Ser; B Dubois; D Galasko; S Gauthier; C G Goetz; E Gomez-Tortosa; G Halliday; L A Hansen; J Hardy; T Iwatsubo; R N Kalaria; D Kaufer; R A Kenny; A Korczyn; K Kosaka; V M Y Lee; A Lees; I Litvan; E Londos; O L Lopez; S Minoshima; Y Mizuno; J A Molina; E B Mukaetova-Ladinska; F Pasquier; R H Perry; J B Schulz; J Q Trojanowski; M Yamada
Journal:  Neurology       Date:  2005-10-19       Impact factor: 9.910

View more
  6 in total

1.  Predictors of Mortality in Individuals with Dementia in the National Alzheimer's Coordinating Center.

Authors:  Melissa J Armstrong; Shangchen Song; Andrea M Kurasz; Zhigang Li
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

2.  Loneliness in older adult mental health services during the COVID-19 pandemic and before: Associations with disability, functioning and pharmacotherapy.

Authors:  Flora Greig; Gayan Perera; Konstantinos Tsamakis; Robert Stewart; Latha Velayudhan; Christoph Mueller
Journal:  Int J Geriatr Psychiatry       Date:  2021-10-06       Impact factor: 3.850

3.  Non-Pharmacological Interventions for Wandering/Aberrant Motor Behaviour in Patients with Dementia.

Authors:  Tatiana Dimitriou; John Papatriantafyllou; Anastasia Konsta; Dimitrios Kazis; Loukas Athanasiadis; Panagiotis Ioannidis; Efrosini Koutsouraki; Thomas Tegos; Magda Tsolaki
Journal:  Brain Sci       Date:  2022-01-19

4.  Clinical outcomes and treatment patterns of older adults with dementia-related psychosis by dementia type in the United States.

Authors:  Joan Forns; Heather E Danysh; Lisa J McQuay; Mary Ellen Turner; Colleen Dempsey; Mary S Anthony; George Demos; J Bradley Layton
Journal:  BMC Geriatr       Date:  2022-10-06       Impact factor: 4.070

5.  Natural language processing in clinical neuroscience and psychiatry: A review.

Authors:  Claudio Crema; Giuseppe Attardi; Daniele Sartiano; Alberto Redolfi
Journal:  Front Psychiatry       Date:  2022-09-14       Impact factor: 5.435

6.  Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: a systematic review.

Authors:  Florindo Stella; Leandro C Lane Valiengo; Vanessa J R de Paula; Carlos Augusto de Mendonça Lima; Orestes V Forlenza
Journal:  Trends Psychiatry Psychother       Date:  2021-07-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.